Table 2 Numbers of regimens used in each treatment line and durations of each treatment line
First-line | Second-line | Third-line | Average durations of treatment (month) | |
|---|---|---|---|---|
Total | 30 | 20 | 8 | 6.5 |
Oxaliplatin-based regimens | 2 | 11 | 3.9 | |
FOLFOX | 2 | 10 | 3.8 | |
XELOX | 1 | 5.0 | ||
Irinotecan-based regimens | 27 | 4 | 8.8 | |
IRIS | 27 | 9.3 | ||
FOLFIRI | 4 | 5.8 | ||
Regimens including molecular targeted agents | 1 | 8 | 2 | 4.3 |
FOLFOX + Bev | 6 | 5.0 | ||
FOLFIRI + Bev or Cet | 1 | 1 | 2 | 4.0 |
XELOX + Bev | 1 | 1.0 | ||
Others | 1 | 2 | 1.3 | |
Average durations of treatment (month) | 9.0 | 3.9 | 3.8 |